E-Mail
A study involving researchers at Karolinska Institutet and Gothenburg University in Sweden has found that low levels of a protein called PDGFRb are associated with particularly good results of radiotherapy in women with early-stage breast cancer. The study, which is published in the journal
Clinical Cancer Research, also suggests that the efficacy of radiotherapy can be improved with drugs that block this protein.
Some 900 women in Sweden are diagnosed with DCIS (ductalcarcinoma in situ), the earliest possible form of invasive breast cancer. Standard treatment is surgery and subsequent radiotherapy. Although the prognosis is generally good, some ten per cent of patients suffer a recurrence within ten years of diagnosis.
rostate canc
er) is a Phase I/IIa study for identification and treatment of PSMA-expressing metastatic castrate resistant prostate cancer (mCRPC), which will be conducted in the U.S. (NCT04868604)
[1]. It is a theranostic multi-centre, single arm, dose escalation study with a cohort expansion planned for up to 44 patients. The trial employs diagnostic Positron Emission Tomography imaging with
64Cu-SAR-bisPSMA for selection of patients suitable for therapy cycles with
67Cu-SAR-bis-PSMA.
Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of death worldwide
[2]. The American Cancer Society estimates in 2021 there will be 248,530 new cases of prostate cancer in the U.S. and around 34,130 deaths from the disease
A recurrence occurs when cancer comes back after treatment. This can happen weeks, months, or even years after the primary or original cancer was treated. It is impossible to know for sure if the cancer will recur and timely detection of recurrence, as well as identification of patients at high risk of recurrence after surgery, can be challenging. Postsurgical circulating tumor DNA (ctDNA) analysis is a promising tool for the identification of patients with minimal residual disease. Now researchers at Massachusetts General Hospital (MGH) report they have evaluated the first test that detects cancer DNA circulating in the blood of patients following treatment without knowing the particular mutations that were present in the patient’s tumor.
Search jobs 30-Apr-2021 Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
SYDNEY, AUSTRALIA – 29 April 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncology’s (ASCO) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 – 8 June.
Study evaluates first tumor-uninformed ctDNA assay to detect residual cancer cells after treatment
After patients with cancer undergo surgery to remove a tumor and sometimes additional chemotherapy, tools are used to identify patients at highest risk of recurrence. Non-invasive tools to detect microscopic disease are of especially high value.
In a new study published in Clinical Cancer Research a team led by investigators at Massachusetts General Hospital (MGH) has evaluated the first tumor-uninformed test that detects cancer DNA circulating in the blood of patients following treatment.
The test, called Guardant Reveal, developed by precision oncology company Guardant Health, is tumor-uninformed because, unlike previous tests for circulating tumor DNA (ctDNA) in the blood, this test does not require knowing the particular mutations that were present in the patient s tumor.